| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1016413154 |
| P356 | DOI | 10.1186/1471-2288-11-61 |
| P932 | PMC publication ID | 3112194 |
| P698 | PubMed publication ID | 21548941 |
| P5875 | ResearchGate publication ID | 51104383 |
| P50 | author | Jeroen P Jansen | Q95974394 |
| P2860 | cites work | Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship | Q28278682 |
| Combination of direct and indirect evidence in mixed treatment comparisons | Q29619499 | ||
| Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancer | Q30886041 | ||
| Flexible meta-regression functions for modeling aggregate dose-response data, with an application to alcohol and mortality | Q30932972 | ||
| Network meta-analysis for indirect treatment comparisons | Q74720205 | ||
| Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study | Q80100963 | ||
| Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer | Q82892839 | ||
| Platinum-based second-line treatment in non-small-cell lung cancer: an old new kid on the block? | Q84941431 | ||
| A new proposal for multivariable modelling of time-varying effects in survival data based on fractional polynomial time-transformation | Q31118240 | ||
| Simultaneous comparison of multiple treatments: combining direct and indirect evidence. | Q34081552 | ||
| Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy | Q34547495 | ||
| Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer | Q34596877 | ||
| Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
| Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy | Q42648649 | ||
| Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. | Q46232500 | ||
| Dynamic Cox modelling based on fractional polynomials: time-variations in gastric cancer prognosis | Q48018580 | ||
| Additive and multiplicative covariate regression models for relative survival incorporating fractional polynomials for time-dependent effects. | Q51830186 | ||
| Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. | Q51835764 | ||
| Borrowing strength from external trials in a meta-analysis. | Q52287071 | ||
| Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. | Q53521886 | ||
| Bayesian measures of model complexity and fit | Q56532420 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | meta-analysis | Q815382 |
| P304 | page(s) | 61 | |
| P577 | publication date | 2011-05-06 | |
| P1433 | published in | BMC Medical Research Methodology | Q15752152 |
| P1476 | title | Network meta-analysis of survival data with fractional polynomials | |
| P478 | volume | 11 |
| Q35651621 | A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis |
| Q30967736 | A multivariate model for the meta-analysis of study level survival data at multiple times |
| Q33830562 | A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer |
| Q93136489 | An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma |
| Q38520487 | Assessing key assumptions of network meta-analysis: a review of methods |
| Q46172005 | Assessing the consistency assumption by exploring treatment by covariate interactions in mixed treatment comparison meta-analysis: individual patient-level covariates versus aggregate trial-level covariates |
| Q39910973 | Bayesian bivariate meta-analysis of correlated effects: Impact of the prior distributions on the between-study correlation, borrowing of strength, and joint inferences |
| Q44317372 | Bayesian indirect and mixed treatment comparisons across longitudinal time points |
| Q38662083 | Bayesian one-step IPD network meta-analysis of time-to-event data using Royston-Parmar models. |
| Q31064714 | Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. |
| Q38988044 | Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
| Q30567158 | Combining individual patient data and aggregate data in mixed treatment comparison meta-analysis: Individual patient data may be beneficial if only for a subset of trials |
| Q31056094 | Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study |
| Q34655407 | Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis |
| Q35097388 | Efficacy and safety of therapies for acute ischemic stroke in China: a network meta-analysis of 13289 patients from 145 randomized controlled trials |
| Q34148380 | Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves |
| Q39342401 | Extrapolation of Survival Curves from Cancer Trials Using External Information. |
| Q30251972 | GetReal in network meta-analysis: a review of the methodology |
| Q90020322 | Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach |
| Q42374085 | Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis. |
| Q57542870 | Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool |
| Q64064747 | Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma |
| Q93059837 | Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia |
| Q34436139 | Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes |
| Q39767823 | Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma |
| Q88757885 | NICE guidance on cabozantinib for previously treated advanced renal cell carcinoma |
| Q35602850 | Network meta-analysis of longitudinal data using fractional polynomials |
| Q57183779 | Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
| Q35056525 | Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making |
| Q27026318 | Recovering the raw data behind a non-parametric survival curve |
| Q64112059 | Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis |
| Q36009462 | Review of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis |
| Q52585940 | Second-line Treatments for Advanced Gastric Cancer: A Network Meta-Analysis of Overall Survival Using Parametric Modelling Methods. |
| Q34557762 | Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide |
| Q26996629 | Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma |
| Q92197712 | Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combinations in COPD |
| Q43884253 | The network meta-analytic-predictive approach to non-inferiority trials |
| Q30239022 | Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis |
| Q89172310 | Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions? |
Search more.